Investment Thesis

. A price drop below $15 or a significant negative earnings report could necessitate a reevaluation of the position.

Competitive Moat

Kenvue benefits from a robust intangible asset moat, largely derived from its established brand portfolio, which includes household names such as Tylenol, Neutrogena, and Listerine. This brand equity creates significant customer loyalty and high switching costs, as consumers are unlikely to shift to less recognized brands for essential health products. The competitive landscape includes threats from both emerging brands and larger incumbents like Procter & Gamble, which could erode market share if not managed effectively. However, Kenvue's strong branding and regulatory expertise provide a durable advantage expected to endure over the next 5-10 years.

Growth Engine

Future revenue growth for Kenvue is expected to stem primarily from organic expansion within its existing segments—Self Care, Skin Health and Beauty, and Essential Health. The total addressable market (TAM) for consumer health products is projected to grow at approximately 5% annually, driven by increasing health consciousness and aging demographics. The company is also exploring new product lines and geographic expansion, particularly in emerging markets, which can further enhance revenue streams. Additionally, Kenvue is gaining market share in the self-care segment, capitalizing on the increasing consumer trend towards over-the-counter health solutions.